ClinicalTrials.gg

Program

sebaloxavir marboxil

Also written as “ZX-7101A”, “ZX-7101A 80mg” and “ZX-7101A and Oseltamivir”.

Its studies are mostly in Influenza, Human, led by Nanjing Zenshine Pharmaceuticals.

Furthest: phase 3, since Jan 16, 202312 company-led studies, 1 open or runningNext primary completion: Dec 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Nanjing Zenshine Pharmaceuticals121 open or runningphase 3since Jan 16, 2023Jan 19, 2022Dec 31, 2027phase 3 · NCT07730346

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 19, 2022First study: phase 1 study in Safety IssuesFirst studyNCT05217732 · 66 enrolled · China
  2. Jan 16, 20232 phase 1 studies in Influenza, HumanNCT05720091, NCT05711797
  3. Jan 16, 2023Phase 3 study in Influenza, HumanNCT05702489 · 900 enrolled · China
  4. Jun 13, 20232 phase 1 studiesNCT05949385, NCT05955027
  5. Sep 12, 2023Phase 1 study in Drug InteractionNCT06057103 · 18 enrolled · China
  6. Oct 19, 2023Phase 3 study in Respiratory Viral InfectionNCT06099873 · 361 enrolled · China
  7. Oct 30, 2024Phase 3 study in Influenza, HumanNCT06669351 · 98 enrolled · China
  8. Feb 13, 2025Phase 1 study in Respiratory Viral InfectionNCT06841926 · 40 enrolled · China
  9. Jul 24, 2025Phase 3 study in Respiratory Viral InfectionNCT07095257 · 169 enrolled · China
  10. Jul 23, 2026Phase 3 study in Influenza PreventionNCT07730346 · 858 planned · China

Ahead

  1. Dec 31, 2027Primary completion: phase 3 study in Influenza PreventionNCT07730346

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07730346Influenza Prevention · China3Not yet recruitingDec 31, 2027858
NCT07095257Respiratory Viral Infection · China3CompletedJan 16, 2026169
NCT06841926Respiratory Viral Infection · China1CompletedApr 18, 202540
NCT06669351Influenza, Human · China3TerminatedJul 15, 202598
NCT06099873Respiratory Viral Infection · China3CompletedFeb 13, 2025361
NCT06057103Drug Interaction · China1CompletedDec 5, 202318
NCT05955027Influenza, Human · China1CompletedAug 5, 202324
NCT05949385Pharmacokinetics · China1CompletedSep 23, 202316
NCT05720091Influenza, Human · China1CompletedMar 20, 20236
NCT05711797Influenza, Human · China1CompletedFeb 6, 202416
NCT05702489Influenza, Human · China3CompletedMay 26, 2023900
NCT05217732Safety Issues · China1CompletedAug 29, 202266

How it is read

Names in the registry

  • “ZX-7101A”, 9 entries
  • “ZX-7101A 80mg”, 2 entries
  • “ZX-7101A and Oseltamivir”, 2 entries
  • “Sebaloxavir marboxil”, 1 entry
  • “ZX-7101A for oral suspension”, 1 entry

Codes read as this program: ZX7101A.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.